PubMed · 2011 · 11 citations · 21 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyOncology PharmacologyPharmacodynamics Of Anticancer AgentsDose-response Curve AnalysisImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingMedian Effective DosePredictive Marker AssessmentSlope Of Dose-response Curve
AIM: To clarify whether class III β-tubulin (TUBB3) is a true predictive marker for chemotherapy with vinorelbine, chemosensitivity was examined using an in vitro drug sensitivity assay. PATIENTS AND METHODS: Initially, 9 specimens were obtained to analyze the dose-response curve and to measure the median effective dose 50 (ED(50)) in the histoculture drug response assay (HDRA). Subsequently, 68 surgically resected non-small cell lung cancer (NSCLC) specimens were applied to the HDRA and H-scores were calculated by immunohistochemical staining. RESULTS: The mean (±SD) slope factor, ED(50) and maximal response was 8.7±5.4, 39.0±17.9 μg/ml and 85.5±5.1% respectively. The mean inhibition rate was 26.4±16.2% and the mean H-score was 1.09±1.07. The inhibition rate was significantly correlated with TUBB3 expression (r=0.27, p=0.03), and was significantly higher in TUBB3-positive specimens than in TUBB3-negative specimens (p=0.003). CONCLUSION: Tumors with high TUBB3 levels exhibited greater chemosensitivity to vinorelbine than tumors with low TUBB3 levels. This finding provides support for the results of the JBR.10 trial.
21
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
J Oan H. S Chiller, D Avid H Arrington, C Handra P. B Elani et al. · 2002 · 3.7K citations
Medicine, Oncology, Pharmacology +11
Jean‐Yves Douillard, Rafael Rosell, Mario De Lena et al. · The Lancet Oncology · 2006 · 1.6K citations
Medicine, Oncology, Pharmacology +12